N
Nick Wadd
Researcher at James Cook University Hospital
Publications - 11
Citations - 441
Nick Wadd is an academic researcher from James Cook University Hospital. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 4, co-authored 8 publications receiving 312 citations. Previous affiliations of Nick Wadd include South Tees Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton,Paul Silcocks,Trevor Cox,Juan W. Valle,Jonathan Wadsley,David Propper,Fareeda Y. Coxon,Paul Ross,Srinivasan Madhusudan,Tom Roques,David Cunningham,Stephen Falk,Nick Wadd,Mark Harrison,Pippa Corrie,Timothy Iveson,A. Robinson,Karen McAdam,Martin Eatock,Jeff Evans,Caroline Archer,Tamas Hickish,Angel Garcia-Alonso,Marianne Nicolson,W.P. Steward,Alan Anthoney,William Greenhalf,Victoria Shaw,Eithne Costello,Dean J. Naisbitt,Charlotte L. Rawcliffe,Gemma Nanson,John P. Neoptolemos +32 more
TL;DR: Adding GV1001 vaccination to chemotherapy did not improve overall survival and new strategies to enhance the immune response effect of telomerase vaccination were not found.
Journal ArticleDOI
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Gary Middleton,Daniel H. Palmer,Daniel H. Palmer,William Greenhalf,Paula Ghaneh,Richard J. Jackson,Trevor Cox,Anthony Evans,Victoria Shaw,Jonathan Wadsley,Juan W. Valle,David Propper,Harpreet Wasan,Stephen Falk,David Cunningham,Fareeda Y. Coxon,R. Paul Ross,Srinivasan Madhusudan,Nick Wadd,Pippa Corrie,Tamas Hickish,Eithne Costello,Fiona Campbell,Charlotte L. Rawcliffe,John P. Neoptolemos +24 more
TL;DR: The addition of vandetanib to gemcitabine monotherapy did not improve overall survival in advanced pancreatic cancer and Tyrosine kinase inhibitors might still have potential in the treatment of pancreas cancer.
Journal ArticleDOI
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
Peter Hall,Peter Hall,Daniel Swinson,David A Cairns,Justin S. Waters,Russell D Petty,Christine Allmark,Sharon Ruddock,Stephen Falk,Jonathan Wadsley,Rajarshi Roy,Tania Tillett,Jonathan Nicoll,Sebastian Cummins,Joseph Mano,Simon Aird Grumett,Zuzana Stokes,Kamposioras Konstantinos-Velios,Anirban Chatterjee,Angel Garcia,Tom Samuel Waddell,Kamalnayan Guptal,Nick Maisey,Mohammed Khan,Jo Dent,Simon Lord,Ann Crossley,Eszter Katona,Helen Marshall,Heike I. Grabsch,Heike I. Grabsch,Galina Velikova,Pei Loo Ow,C. Handforth,Helen Howard,Matthew T. Seymour,Matthew T. Seymour,Go Trial Investigators,Go Trial Investigators,Eleanor James,Sue Cheeseman,Tom Roques,Nicholas S. Reed,Charles Candish,D. Fyfe,Richard Ellis,Lesley Samuel,Rebecca Herbertson,Louise Medley,Kinnari Patel,David Sherriff,A. Robinson,Pavel Bezecny,Dunca Wilkins,Adam McGeoch,Daniel Propper,Olwyn Williams,Serena Hilman,Sherif Raouf,Claire Hobbs,Jo Parkinson,Nick Wadd,W Saku,Victori Kunene,Colin Askill,Arshad Jamil,Emma Cattell,Lauren Gorf,Vallipuram Vigneswaran,Erica Beaumont,Syed Zubair,Elin Jones,Nicholas Reed,Alaaeldin Shablak,George Bozas,Sheela Rao,Michael Bennet,Joanne Askey,Gareth Griffiths,Sally Clive,Vanessa Potter,Jean Gall,Chris Twelves,Matthew R. Sydes,Juan W. Valle,Jo Webster,Marc Jones,Fiona Collinson,Julia Brown,Louise Brook +89 more
TL;DR: The CHEMO-INTENSITY randomized clinical trial as discussed by the authors found that reduced-intensity chemotherapy provided a better patient experience without significantly compromising cancer control and should be considered for older and/or frail patients.
Journal ArticleDOI
Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).
Matthew T. Seymour,Sarah Brown,Susan D. Richman,Gary Middleton,Tim Maughan,Catherine Olivier,Stephen J. Gwyther,Jonathan Wadsley,Ian Chau,Tamas Hickish,L K Dawson,S Falk,Ann O'Callaghan,Kim Benstead,Nick Wadd,Alfred Oliver,Philip A. Chambers,H Marshall,Vicky Napp,Philip Quirke +19 more
TL;DR: PICCOLO did not meet its primary endpoint of improved OS with panitumumab inKRAS-wt aCRC, but a trend was seen towards survival benefit after 12 months, especially in KRAS/BRAF-wt pts, and planned molecular subgroups shows worse survival, and disbenefit with Pan in BRAF-mut pts.
Journal ArticleDOI
COVID-19 and liver cancer: lost patients and larger tumours
Daniel Geh,Robyn Watson,Gourab Sen,Jeremy French,John Hammond,P Turner,Tim Hoare,Kirsty E. Anderson,Michael J. McNeil,Stuart McPherson,Steven Masson,Jessica K Dyson,Mhairi C Donnelly,L. MacDougal,Preya J. Patel,Mark Hudson,Quentin M. Anstee,S. N. White,Stuart Robinson,Sanjay Pandanaboyana,Lucy J. Walker,Misti Vanette McCain,Yvonne Bury,Shreya Raman,Alastair D. Burt,Daniel Parkinson,Beate Haugk,Antony Darne,Nick Wadd,Syed Parvez Asghar,Lavanya Mariappan,Jane Margetts,Ben Stenberg,John Scott,Peter Littler,Derek Manas,Helen L. Reeves +36 more
TL;DR: The pandemic-associated reduction in referred patients in the authors' region was attributed to the disruption of routine healthcare, and it is recommended routine healthcare services continue, with patients encouraged to engage.